AVEO - AVEO Pharmaceuticals, Inc.
| Previous Close | 2.65 |
| Open | 2.65 |
| Bid | 2.57 x 400 |
| Ask | 2.64 x 2000 |
| Day's Range | 2.56 - 2.67 |
| 52 Week Range | 0.57 - 4.24 |
| Volume | 1,292,757 |
| Avg. Volume | 1,889,147 |
| Market Cap | 399.254M |
| Beta | 1.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.61 |
| Earnings Date | May 11, 2017 - May 12, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.67 |
- Zacks•9 days ago
AVEO Down 7.7% Since Earnings Report: Can It Rebound?
AVEO reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Motley Fool•12 days agoWhy AVEO Oncology Jumped Higher Today
Investors see value after last week's decline.
- ACCESSWIRE•15 days ago
Today’s Research Reports on Trending Tickers: AVEO Pharmaceuticals and Neovasc
NEW YORK, NY / ACCESSWIRE / April 6, 2018 / U.S. markets ended higher on Thursday for their third straight daily gain as technology stocks recover from a series of shortcomings. The Dow Jones Industrial ...
- Zacks•16 days ago
Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)
Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)
- Business Wire•26 days ago
AVEO Oncology to Present at Upcoming Conferences
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences:
- Zacks•29 days ago
Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
AVEO Pharmaceuticals (AVEO) needs investors to pay close attention to the stock based on moves in the options market lately.
- Business Wire•last month
AVEO Oncology Announces Publication of Long-term Follow-up Results from TIVO-1 Extension Study (Study 902) in TKI Refractory RCC
AVEO Oncology today announced the publication of long-term follow-up results from Study 902, where patients were treated with tivozanib as second-line treatment in advanced renal cell carcinoma , in the European Journal of Cancer.
- Zacks•last month
AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down
AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the fourth quarter with revenues missing estimates. The top line also declines year over year.
- Associated Press•last month
AVEO posts 4Q profit
On a per-share basis, the Cambridge, Massachusetts-based company said it had profit of 8 cents. The cancer drug company posted revenue of $82,000 in the period. For the year, the company reported that ...
- Business Wire•last month
AVEO Reports Full Year 2017 Financial Results and Provides Business Update
AVEO Oncology today reported financial results for the full year ended December 31, 2017 and provided a business update.
- GlobeNewswire•last month
Investor Expectations to Drive Momentum within AVEO Pharmaceuticals, PTC Therapeutics, NGL Energy Partners LP, Bemis, CorMedix, and Patterson Companies — Discovering Underlying Factors of Influence
NEW YORK, March 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Zacks•2 months ago
AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?
AVEO Pharmaceuticals (AVEO) launched its first drug, Fotivda, as first-line treatment for RCC in Europe in November. This is likely to have a favorable impact on fourth-quarter results.
- Business Wire•2 months ago
AVEO Oncology to Present at the Cowen and Company 38th Annual Health Care Conference
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the Cowen and Company 38th Annual Health Care Conference in Boston on Tuesday, March 13, 2018 at 10:40 a.m.
- ACCESSWIRE•2 months ago
Today’s Research Reports on Trending Tickers: AVEO Pharmaceuticals and Exelixis
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / U.S. markets spiked to session highs after minutes from the Fed's January meeting were released, but then dropped as yields for the 10-year Treasury note ...
- Zacks•2 months ago
AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda
AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).
- ACCESSWIRE•2 months ago
Blog Exposure - AVEO Announced Positive NICE Recommendation for FOTIVDA(R) as First Line Treatment for Advanced Renal Cell Carcinoma
Stock Monitor: Bio-Techne Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 14, 2018 / Active-Investors.com has just released a free research report on AVEO Pharma, Inc. (NASDAQ: AVEO ). If you ...
- Business Wire•2 months ago
AVEO Announces EUSA Pharma Granted Positive NICE Recommendation for FOTIVDA® (tivozanib) as First Line Treatment for Advanced Renal Cell Carcinoma
AVEO Oncology today announced that the United Kingdom’s National Institute for Health and Care Excellence has published a Final Appraisal Determination recommending FOTIVDA® for the first line treatment of adult patients with advanced renal cell carcinoma .
- Business Wire•2 months ago
AVEO Oncology and EUSA Pharma Announce Encouraging Preliminary Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma
AVEO Oncology and EUSA Pharma today announced the presentation of preliminary results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral tivozanib in combination with intravenous nivolumab , an immune checkpoint, or PD-1, inhibitor, for the treatment of metastatic renal cell carcinoma .
- Business Wire•2 months ago
AVEO Oncology to Present at Upcoming Conferences
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences:
- Business Wire•3 months ago
AVEO Announces Appointment of John H. Johnson to Board of Directors
AVEO Oncology today announced the appointment of John H. Johnson to the Company’s Board of Directors. Mr. Johnson brings to AVEO over three decades of experience in the biotechnology and pharmaceuticals industries, having held commercial and executive management roles at leading global corporations that have a focus on oncology, including Johnson & Johnson, Eli Lilly & Company, ImClone Systems, Dendreon ...
- Simply Wall St.•3 months ago
How Much is AVEO Pharmaceuticals Inc’s (NASDAQ:AVEO) CEO Getting Paid?
Michael Bailey took the helm as AVEO Pharmaceuticals Inc’s (NASDAQ:AVEO) CEO and grew market cap to $363.25M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
- ACCESSWIRE•3 months ago
Blog Exposure - AVEO Pharma Presents Data from Phase-1b/2 Study of Tivozanib in Patients with Advanced HCC
LONDON, UK / ACCESSWIRE / January 23, 2018 / Active-Investors.com has just released a free research report on AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO ) ("AVEO"). If you want access to this report ...
- Business Wire•3 months ago
AVEO Oncology Announces Presentation of Data from Phase 1b/2 Study of Tivozanib in Patients with Advanced Hepatocellular Carcinoma
AVEO Oncology today announced the presentation of data from a multicenter, Phase 1b/2 study of FOTIVDA® , a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor receptors, in patients with advanced, unresectable hepatocellular carcinoma .
- ACCESSWIRE•3 months ago
Today’s Research Reports on Trending Tickers: AVEO Pharmaceuticals and Opko Health
NEW YORK, NY / ACCESSWIRE / January 17, 2017 / Early gains from the major indexes were erased Tuesday as political concerns weighed down the market's recent rally. The Dow Jones Industrial Average declined ...
- Motley Fool•3 months ago
Here's Why AVEO Oncology Rose as Much as 13.7% Today
The company is fresh off a presentation at the J,P. Morgan Healthcare Conference.
